3737.Hk
3737.HK is a pharmaceutical company that generates revenue primarily through the development, production, and sale of pharmaceutical products.
Business. 3737.HK is a pharmaceutical company that generates revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
3737.HK is a pharmaceutical company that generates revenue primarily through the development, production, and sale of pharmaceutical products.
The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.12, indicating a conservative leverage position. Its liquidity is assessed as medium, with a current ratio of 1.6, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if not managed effectively.
Profitability metrics show a return on equity (ROE) of 1.58% and a return on assets (ROA) of 0.94%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's gross profit margin is 54.1%, which is in line with industry norms, but its operating margin is only 1.4%, indicating significant operating expenses relative to revenue.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher risk if market conditions in its primary operating region change.
The company's growth trajectory is not clearly defined in the available data, as there are no specific projections or historical revenue growth rates provided. The absence of detailed growth metrics makes it difficult to assess the company's future performance relative to its peers.
The company's risk profile includes a medium liquidity risk and a low dilution risk. The risk assessment highlights that the company's net cash is negative after subtracting total debt, which could affect its ability to meet short-term obligations. No significant dilution sources are identified in the available data, and the company's shares outstanding have not changed between basic and diluted figures.
Recent events and filings are not detailed in the available data, so no specific recent developments can be reported. The company's financial statements do not include any notable events or transcripts that would provide insight into recent strategic or operational changes.
- The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.12.
- Profitability is weak, with a return on equity of 1.58% and a return on assets of 0.94%.
- The company's revenue is not diversified across segments or geographies, increasing exposure to regional market risks.
- Liquidity is assessed as medium, with a current ratio of 1.6, but the company has a negative net cash position after debt.
- No significant dilution risk is identified, and shares outstanding remain unchanged between basic and diluted figures.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 3737.HK Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Ying Feng LaiChief Executive Officer, Executive Director
- Zhi Tian Zhi LaiExecutive Chairman of the Board